Bevantolol - SOM Biotech

Drug Profile

Bevantolol - SOM Biotech

Alternative Names: SOM3355

Latest Information Update: 31 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nippon Chemiphar
  • Developer SOM Biotech
  • Class Antihypertensives; Ischaemic heart disorder therapies; Small molecules
  • Mechanism of Action Vesicular monoamine transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Clinical Phase Unknown Huntington's disease

Most Recent Events

  • 30 Oct 2017 Chemical structure information added
  • 11 Oct 2017 Bevantolol licensed to SOM Biotech worldwide except Asia
  • 11 Oct 2017 SOM Biotech intends to initiate a phase IIa proof-of-concept trial for Huntington's disease in Europe, in December 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top